The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
123872222 12387222 2 F 20130130 20160714 20160519 20160721 EXP US-DSJP-DSU-2016-116609 DAIICHI 0.00 Y 0.00000 20160721 MD US US

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
123872222 12387222 1 PS BENICAR OLMESARTAN MEDOXOMIL 1 Oral 20 MG, QD Y 21286 20 MG TABLET QD
123872222 12387222 2 SS BENICAR OLMESARTAN MEDOXOMIL 1 Oral 40 MG,BID Y 21286 40 MG TABLET BID
123872222 12387222 3 C MAALOX ANTACID ALUMINUM HYDROXIDEDIMETHICONEMAGNESIUM HYDROXIDE 1 30 ML, ONCE EVERY 6HR 0 30 ML ORAL SUSPENSION Q6H
123872222 12387222 4 C NEXIUM ESOMEPRAZOLE MAGNESIUM 1 Oral 40 MG, QD 0 40 MG QD
123872222 12387222 5 C ANTIVERT /00007101/ MECLIZINE MONOHYDROCHLORIDENIACIN 1 Oral 25 MG, PRN 0 25 MG TABLET
123872222 12387222 6 C KETOCONAZOLE. KETOCONAZOLE 1 Topical 2 %, BID 0 2 PCT CREAM BID
123872222 12387222 7 C LASIX FUROSEMIDE 1 Oral 40 MG, QD 0 40 MG TABLET QD
123872222 12387222 8 C FAMOTIDINE. FAMOTIDINE 1 Oral 20 MG, UNK 0 20 MG TABLET BID
123872222 12387222 9 C FAMOTIDINE. FAMOTIDINE 1 0 TABLET
123872222 12387222 10 C ACETAMINOPHEN. ACETAMINOPHEN 1 Oral 325 MG, ONCE EVERY 4HR 0 325 MG TABLET Q4H
123872222 12387222 11 C ACETAMINOPHEN. ACETAMINOPHEN 1 Oral 650 MG, ONCE EVERY 4HR 0 650 MG TABLET Q4H
123872222 12387222 12 C LIDOCAIN /00033401/ LIDOCAINE 1 Topical 5 %, UNK 0 5 PCT

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
123872222 12387222 1 Hypertension
123872222 12387222 3 Abdominal discomfort
123872222 12387222 4 Product used for unknown indication
123872222 12387222 5 Dizziness
123872222 12387222 6 Onychomycosis
123872222 12387222 7 Diuretic therapy
123872222 12387222 8 Pancreatic insufficiency
123872222 12387222 9 Gastrooesophageal reflux disease
123872222 12387222 10 Pain
123872222 12387222 11 Body temperature increased
123872222 12387222 12 Product used for unknown indication

Outcome of event

Event ID CASEID OUTC COD
123872222 12387222 HO
123872222 12387222 OT

Reactions reported

Event ID CASEID DRUG REC ACT PT
123872222 12387222 Coeliac disease
123872222 12387222 Colon adenoma
123872222 12387222 Diverticulum intestinal
123872222 12387222 Dizziness
123872222 12387222 Gastrooesophageal reflux disease
123872222 12387222 Haematochezia
123872222 12387222 Hiatus hernia
123872222 12387222 Malabsorption
123872222 12387222 Pancreatic disorder
123872222 12387222 Pyrexia

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
123872222 12387222 1 20130513 201404 0
123872222 12387222 2 20130513 201404 0